Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -8 of 8
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/11/2008
 
First Published:
6/1/1999
1.
Phase III Randomized Study of High-Dose Aldesleukin With or Without gp100 Antigen in Patients With Locally Advanced or Metastatic Cutaneous Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
CCCGHS-NCI-T98-0085
NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682
Last Modified:
10/31/2008
 
First Published:
11/1/1999
2.
Phase II Study of Adoptive Transfer of Cloned Lymphocytes With Interleukin-2 After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
16 and over
NCI
NCI-99-C-0158
NCI-T99-0078, T99-0078, NCT00019942
Last Modified:
11/16/2008
 
First Published:
5/28/2004
3.
Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
MCC-15241
MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036
Last Modified:
11/16/2008
 
First Published:
5/28/2004
4.
Phase II Randomized Study of Immunization With Autologous Dendritic Cells (DC) Pulsed With gp100 Antigen Versus Autologous DC Fused With Autologous Tumor Cells in Patients With Stage III or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Any age
NCI
DFCI-03123
NCT00085397
5.
Melanoma Vaccine With Peptides and Leuprolide
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
2004-0502
NCT00254397
Last Modified:
11/17/2008
 
First Published:
3/13/2006
6.
Phase II Randomized Study of Adjuvant gp100 Peptide Immunization With or Without Montanide ISA 51 and/or Imiquimod in Patients With Resected High-Risk Melanoma (Treatment Arms I-IV Closed to Accrual as of 1/11/08)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
16 and over
NCI
NCI-06-C-0069
7676, NCI-7676, NCI-P6703, NCT00304057
Last Modified:
11/18/2008
 
First Published:
8/24/2004
7.
Phase I Randomized Pilot Study of Fludarabine Followed By Vaccination Comprising Modified gp100 Peptide, Montanide ISA-51, and Keyhole Limpet Hemocyanin Combined With Autologous Peripheral Blood Mononuclear Cell Reinfusion in Patients With Unresectable or Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
NCI
PPMC-IRB-02-99
NCI-6361, 6361, NCT00091143
8.
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
Over 18
Other
Pro00000806
IND # BB-13545, NIH OBA # 0708-874, NCT00672542
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute